Skip to content
OpenCapital
Get started

Zoetis ZTS Anti-infectives — Revenue

Other product segments

Horses
$5.8B+13.9%
Dogs and Cats
$1.35B+11.6%
Parasiticides
$586M+2.4%
Vaccines
$519M+18.2%
Cattle
$399M-0.5%
Dermatology
$349M-7.9%
Pain and sedation
$203M-1.9%
Other pharmaceutical
$158M0.0%
Swine
$128M-7.9%
Animal health diagnostics
$117M+12.5%
Poultry
$117M-7.9%
Other Non Pharmaceuticals
$66M-7.0%
Fish
$65M+4.8%
Contract manufacturing & human health
$23M-23.3%
Sheep and other
$17M+6.3%

Similar metrics at other companies

Phibro Animal Health logo
PAHCAnimal Health — Revenue
$291.23M+12.7%
Johnson & Johnson logo
JNJOther Infectious Diseases — Sales to customers (Note 9)
$37M-9.8%
Cencora logo
CORAnimal Health — Revenue
$1.44B+5.3%
Elanco Animal Health Inc. logo
ELANFarm Animal: — Revenue
$642M+17.6%
AMP
AMPHPharmaceutical Products — Revenue
$171.17M+0.4%
Phibro Animal Health logo
PAHCVaccines — Revenue
$38.63M+15.7%

Other financials

Income statement

See full
Revenue$2.3B+2.9%
Gross profit$1.6B+2.6%
Net income$601.0M-0.2%
EPS (diluted)$1.42+6.0%

Balance sheet

See full
Cash & equivalents$1.9B+8.9%
Total debt$10.0B+48.0%
Total equity$3.2B-30.5%
Total assets$15.2B+7.5%

Cash flow

See full
Operating cash flow$401.0M-22.1%
CapEx$110.0M-38.2%
Free cash flow$291.0M-13.6%

Valuation

See full
Market cap$31.9B-54.6%
Enterprise value$39.95B-47.2%
P/E12.1×-15.1×
P/S3.4×-4.1×

Profitability

See full
Gross margin71.8%+0.8pp
Net margin27.8%+0.9pp
FCF margin23.5%0.0pp

Returns & leverage

See full
Return on equity67%+15.8pp
Debt / equity3.1×+1.6×
Current ratio3.2×+1.4×

Where this comes from

Reported directly by Zoetis in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Zoetis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zoetis's anti-infectives — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zoetis's anti-infectives — revenue?
Zoetis (ZTS) reported anti-infectives — revenue of $241M in Q1 2026.
How has Zoetis's anti-infectives — revenue changed year-over-year?
Zoetis's anti-infectives — revenue increased by 1.3% year-over-year, from $238M to $241M.
What is the long-term trend for Zoetis's anti-infectives — revenue?
Over 4 years (2021 to 2025), Zoetis's anti-infectives — revenue has grown at a -4.2% compound annual growth rate (CAGR), from $1.22B to $1.03B.
What does anti-infectives — revenue mean?
This metric represents the total gross sales generated from the sale of anti-infective pharmaceutical products, including antibiotics and related treatments, designed to prevent or treat infections in animals. It serves as a key indicator of the company's market penetration and demand within the veterinary therapeutic segment. Fluctuations in this revenue stream often reflect changes in disease prevalence, competitive pricing pressures, and the adoption rate of the company's specific anti-infective portfolio.